HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers - Wikidata - awgldk - TriplyDB

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

http://www.wikidata.org/entity/Q28647225

about

HIV-Host Interactions: Implications for Vaccine Design Harnessing the protective potential of HIV-1 neutralizing antibodies Recent update in HIV vaccine development Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens Immune correlates of vaccine protection against HIV-1 acquisition The HIV glycan shield as a target for broadly neutralizing antibodies Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Elimination of HIV-1-infected cells by broadly neutralizing antibodies Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Current views on the potential for development of a HIV vaccine.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers An overview of the lagomorph immune system and its genetic diversity.Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins CXCL13 is a plasma biomarker of germinal center activity.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

P2860

Q26765966-CFB1B866-4BFB-4B64-A260-2B18E59772BB Q26766153-7253E990-03E7-4DFD-9913-675CCA1F8755 Q26766628-8319377B-5EF3-4B9E-A013-B685D540872E Q26777382-A14AFBF4-7423-4440-93D6-0DF997BCA0C5 Q26778573-AC0E08F3-57DD-473B-8DB5-8697E089E2E6 Q26786540-8DE1CDB5-B1E2-4B17-B58E-009DAEF53DA0 Q27319450-F23872B8-6090-4A2E-A692-C322CE9AF932 Q27329126-6FF59BC9-8E81-4A4C-BF85-AB02079FCF14 Q27644634-CC4B5411-00AF-4843-A894-4D60088335B4 Q27704710-E4AC40D6-EC07-46F5-B7FB-6F376DB2AA6C Q28075274-9ABD8652-AB81-4005-BD4B-7A51707F3330 Q28271300-67D5EDE4-D263-4D67-83CD-A5FA7F72C00F Q28553360-9D2AEEA7-907C-43ED-8EAA-DCC163A33EC0 Q28804076-D9CBB3F8-6D8E-4202-A137-9779EE9C689F Q29306052-F0A1F214-1CF2-49DD-BFEF-205637985AD0 Q30234773-21837ABE-C1F6-45F1-BF0E-D659F388BEB3 Q30397595-B89881BD-1498-46CC-9BDB-01EBB424EA1D Q30490942-F58E88B9-6236-4CD7-9F5D-559A51DF0221 Q32183108-F4060091-F837-4E3E-B9F4-8A89A684C9FA Q33612459-49D9CBA5-4CF1-4086-B103-6491F8228E42 Q33753573-51CF8A0F-98B6-415C-96AD-4453F4C2D3E5 Q33821896-1F4ADA82-D4F8-4723-AE8D-C42859A6475B Q33830824-A898BC17-267E-41DB-907B-21DD793D5F1A Q33907694-0E364D5F-2EED-42AA-B0E8-2A17C94B42C5 Q35785529-E5B1F8C2-B0C1-4CC9-BB95-8B109B982D28 Q36050577-F1E38F93-DEFF-4D3B-92A2-C4D4CBE64EA9 Q36086357-CFA4F6D9-7228-49ED-AF82-62D3E94345E6 Q36094699-0164A3F3-D5E9-4E32-93D4-022C1D6DE768 Q36102994-4C695121-D1F2-4A33-919F-63CABFAAE11C Q36112751-53FDC00D-7B29-44D5-A198-BEC477E6D02E Q36132706-0763B1EA-BFC3-4585-8FE6-DCFFEB117B5B Q36194234-BCE1D50D-A921-4712-8003-BF00DAC3714C Q36303368-6165EEFF-DDC6-4AD3-B4B7-79835C5B1333 Q36334359-74F3225B-1915-41FE-89E0-ECDD6CB07FC8 Q36409575-98CEE0C2-719B-4918-9A6C-30E120C569C0 Q36434196-1D4E1874-1D93-4830-A863-2DEDF3028B69 Q36446733-35CE22D3-95EC-4CED-BA23-36C813DC68AE Q36481537-7F926792-A509-431B-98DA-EABC67489A59 Q36684710-E6C4C068-C5AC-4D0B-B8CF-AFBEBBA5B5BC Q36702114-0BC7B06D-3AE5-4537-841B-7B0E8F2A3232

P2860

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

http://www.wikidata.org/entity/Q28647225

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@ast

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@en

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@nl

type

label

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@ast

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@en

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@nl

prefLabel

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@ast

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@en

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@nl

P1433

Q28647225-12155F9D-DE52-4593-827B-430E8B319C00

P1476

Q28647225-2B403C83-37C7-47F9-841A-B0833ECC4193

P2093

Q28647225-0029905D-0AA2-4DB3-9A20-8B4E1B4FFD15

Q28647225-0BFCF5D3-C69C-4694-B238-FD200CFF053E

Q28647225-2FBB7601-A60D-4F6A-83DA-357E05A80280

Q28647225-3E5EABB9-FE5B-4B66-BF40-D8F77938D7C7

Q28647225-40845D4B-6253-43AF-B53A-152D28368333

Q28647225-46434AA2-E5BC-47F9-93B3-E1CDACCECCD7

Q28647225-6A7C504C-8799-4329-A81B-E2D4AC53CAB1

Q28647225-78CC9BFD-81A0-4B38-A0CC-12C18A09A1E3

Q28647225-791AC584-46C1-4A64-805B-0849BE406004

Q28647225-80A4B159-F794-4482-ADB5-FB1A361071AB

P2860

Q28647225-006618A8-5986-4641-A95B-E9600AF19142

Q28647225-039EE4EB-ED42-4801-969F-F55B15E3FD4E

Q28647225-051528E5-CC71-47B8-8A8E-0240BED12457

Q28647225-07C2B646-8025-4FA2-BC52-730490A8CFC2

Q28647225-08A1A8F6-2147-44B1-BEB0-379F039D3506

Q28647225-0B473121-197F-41E7-AD70-AC25F685A98A

Q28647225-11282E1E-8397-4F76-8B0B-22415FC06209

Q28647225-2137AF41-3F28-4E2B-B56F-6D6B92B13A08

Q28647225-2418EE81-1C75-4C55-A747-4EC688933A9A

Q28647225-25DCC153-DD83-449B-B52C-EAA7BB496BB0

P304

Q28647225-F9026237-3E07-4A5F-83DA-39E08C3AD6D0

P31

Q28647225-E18C0933-220A-4CC9-82B7-12F10B3021DA

P3181

Q28647225-9CACE7B3-C567-4717-8CA2-BEE206D7DE85

P356

Q28647225-FBDAC150-FF81-468B-BDE6-4F1AC2CBF128

P407

Q28647225-78D0AE35-A6B4-4742-A8A5-B915E28B94AF

P433

Q28647225-F5A408EF-1DF3-4FF4-BA89-64F399D6F607

P478

Q28647225-F258C6F7-01C5-46A6-A6EF-B5D05F3B246D

P50

Q28647225-056F10C2-89F6-4A4C-983A-2A19E00B55E2

Q28647225-2102E545-D2E0-47CA-9547-663994C25436

Q28647225-81213095-FEE8-4DBD-B207-A40C34BFDC8E

Q28647225-A03917F7-819F-4A92-8DA1-0ED9C98B72DF

Q28647225-A47DE651-5373-4C38-9764-71682C577663

Q28647225-C03935ED-9EA7-433F-970A-977197F64126

Q28647225-DEF3E70C-6911-487D-B3C7-15BF33969360

Q28647225-F130BBFE-FD64-4C83-A721-3B2B13DB0E5C

P577

Q28647225-4B44CC99-2A3D-470E-AC39-635BA982F4A6

P5875

Q28647225-DC24BDED-8EBC-4313-9290-8CAC2D847898

P698

Q28647225-E5BCB159-F665-4090-930F-D841F574B4C9

P921

Q28647225-723AE930-B23E-470B-8FB4-21A421BEEBAF

Q28647225-8C400772-365A-47E6-814A-E088A1F1F0C1

P932

Q28647225-D7F413C7-9C46-48AA-95F5-43C871B3FB53

P3181

P356

SCIENCE.AAC4223

P1433

P1476

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

@en

P2093

Albert Cupo

http://www.w3.org/2001/XMLSchema#string

Andrew B Ward

http://www.w3.org/2001/XMLSchema#string

Brian Moldt

http://www.w3.org/2001/XMLSchema#string

Celia LaBranche

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Devin Sok

http://www.w3.org/2001/XMLSchema#string

Eva G Rakasz

http://www.w3.org/2001/XMLSchema#string

Gabriel Ozorowski

http://www.w3.org/2001/XMLSchema#string

Gargi Debnath

http://www.w3.org/2001/XMLSchema#string

Gözde Isik

http://www.w3.org/2001/XMLSchema#string

P2860

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign

P304

aac4223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

190536

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.AAC4223

http://www.w3.org/2001/XMLSchema#string

P407

P433

6244

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Philippe Julien

Marit J van Gils

Cassandra Simonich

Ian Andrew Wilson

Julie Overbaugh

David C Montefiori

P577

2015-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280032613

http://www.w3.org/2001/XMLSchema#string

P698

26089353

http://www.w3.org/2001/XMLSchema#string

P921

P932

4498988

http://www.w3.org/2001/XMLSchema#string